EGFR and non-small cell lung carcinoma: Interestingly, combining ACLY knockdown and statin treatment also blocked PI3k/Akt and Mitogen Activated Protein Kinase (MAPK) signaling in EGFR and K-Ras mutant NSCLC lines [45].